Oncology

For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival

September 28, 2009
Charles Coombes

Charles Coombes

Charles Coombes at ECCO15-ESMO34 on the Intergroup Exemestane Study showing a big increase in survival for patients with early breast cancer randomized to have their adjuvant therapy switched to exemestane after 2-3 years of tamoxifen, compared with those who remained on tamoxifen for the entire 5 years of endocrine therapy.

Download this interview

Add podcast to iTunes

Similar Interviews

  • Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!

    • [caption id="attachment_990" align="alignnone" width="120" caption="Cornelis van de Velde"][/caption]Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase

  • ASCO Audio Journal of Oncology in Advance – February 15th, 2007 – reporting from San Antonio Breast Cancer Symposium, December 13-17, 2007

    • Rachel Johnson

  • Audio Journal of Oncology 13.3, April 2005

    • Reporting from: - American Society of Hematology 46th Annual Meeting, December 4-7, 2004, San Diego - San Antonio Breast Cancer Symposium, December

    Post a comment